Early Intervention Coaching for Infants at Risk of Autism
(PETAL Trial)
Trial Summary
What is the purpose of this trial?
The proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes at 24 months. Results of this study will determine when (9 vs 12 vs 15 months), and based on which measures (brain, language, or their combination) to augment parental support with a specialized parent-mediated coaching intervention for optimal outcomes on communication and language at 24 months. Children will be recruited at 6-8 months of age and will begin with entry assessments. All children will first begin with the MONITOR condition (using Ages \& Stages Questionnaire (ASQ-3) and activity cards. Then when the child is 9 months, they will be randomized to continue with MONITOR condition or COACH condition (incorporates JASPER intervention and Babble Bootcamp) after second set of assessments. There are a total of 6 assessment timepoints (6-8 months of age, 9 months of age, 12 months of age, 15 months of age, 18 months of age, and 24 months of age). At time points of 9months and 12 months, the child will be randomized to COACH or MONITOR conditions. Once the child is randomized to COACH condition, they will continue with that condition until they terminate the study at 24 months. At the 15 months timepoint, there will no longer be a randomization. Children that were in the MONITOR condition will change to the COACH condition until they terminate the study.
Will I have to stop taking my current medications?
The trial does not specify if participants must stop taking their current medications. However, infants who are not stable on anti-seizure medication are excluded, which suggests that stable medication use might be allowed.
What data supports the effectiveness of the treatment Babble Bootcamp, Babble Bootcamp, Babble Plus, JASPER, Joint Attention Symbolic Play Engagement & Regulation for infants at risk of autism?
Research shows that early interventions focusing on joint attention and play, like JASPER, can improve social skills and language development in young children with autism. Additionally, involving parents in early intervention and tailoring the approach to each child's needs are effective strategies for supporting infants at risk of developmental challenges.12345
Is the Early Intervention Coaching for Infants at Risk of Autism safe for humans?
How does the early intervention coaching treatment for infants at risk of autism differ from other treatments?
Research Team
Eligibility Criteria
This trial is for infants aged 6-8 months who are at risk for autism because they have an older sibling with the condition. They must come from very low-income families in Los Angeles and not have seizures, physical disorders, other syndromes or diseases, sensory or motor impairments, genetic syndromes like Down Syndrome, or be born before 34 weeks of gestation.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Baseline demographic, language, behavior, and brain assessments are conducted
Phase 1: MONITOR Condition
All children begin with the MONITOR condition using Ages & Stages Questionnaire (ASQ-3) and activity cards
Phase 2: Randomization to MONITOR or COACH
Children are randomized to continue with MONITOR or transition to COACH condition
Phase 3: Continued Intervention
Children not yet transitioned to COACH are randomized again; others continue their assigned condition
Phase 4: All Transition to COACH
All remaining children transition to the COACH condition
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Babble Bootcamp (Behavioural Intervention)
- JASPER (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, Los Angeles
Lead Sponsor
Dr. Thomas Rando
University of California, Los Angeles
Chief Medical Officer since 2023
MD from UCLA
Amir Naiberg
University of California, Los Angeles
Chief Executive Officer since 2024
JD from UCLA
University of Massachusetts, Worcester
Collaborator
Dr. Eric W. Dickson
University of Massachusetts, Worcester
Chief Executive Officer since 2013
MD from UMass Chan Medical School, Master's in Health Care Management from Harvard University
Dr. Andy Karson
University of Massachusetts, Worcester
Chief Medical Officer
MD